



Trial Information Summary

ALLG Trial Number:	NHL29
Trial Name:	A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL
Lay Summary:	<p>The purpose of this study is to assess the effects, both good and bad, of Ibrutinib when it is given together with rituximab, and reduced doses of cyclophosphamide, doxorubicin, vincristine, and prednisone (abbreviated as R-mini-CHOP) in very elderly patients aged more than 75 years who have been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), the most common type of Non Hodgkins Lymphoma.</p> <p>With the increase in our aging population, DLBCL in the elderly will become more common and R-mini-CHOP chemotherapy is considered a standard treatment for this group of patients. Given the excellent tolerability of Ibrutinib in other lymphoma studies and early data supporting its benefit for the most common subtype of DLBCL, the aim is to improve the survival of the elderly patient by adding Ibrutinib to R-mini-CHOP.</p>
Participating Hospitals:	1. Ballarat Oncology & Haematology / 2. Box Hill / 3. Calvary Mater Newcastle / 4. Concord / 5. Fiona Stanley / 6. Flinders Medical Centre / 7. Gold Coast / 8. Nepean / 9. Orange Health Service / 10. Princess Alexandra / 11. Royal Brisbane and Women's / 12. Royal Hobart / 13. Royal Prince Alfred / 14. Sir Charles Gairdner / 15. St Vincent's Melbourne / 16. Westmead / 17. Wollongong
Target Accrual (International)	n/a
Target Accrual (ALLG)	80
Expected Final Accrual Date:	September 2018